Kingfisher Capital’s Gilead Sciences GILD Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2020
Q3
Sell
-20,744
Closed -$1.6M 158
2020
Q2
$1.6M Buy
20,744
+2,569
+14% +$197K 0.71% 50
2020
Q1
$1.36M Buy
+18,175
New +$1.26M 0.7% 48
2019
Q2
Sell
-3,269
Closed -$213K 126
2019
Q1
$213K Buy
3,269
+30
+0.9% +$1.99K 0.14% 118
2018
Q4
$203K Buy
3,239
+127
+4% +$8.88K 0.14% 122
2018
Q3
$240K Sell
3,112
-262
-8% -$19.8K 0.13% 121
2018
Q2
$239K Buy
3,374
+333
+11% +$23.5K 0.15% 122
2018
Q1
$229K Hold
3,041
0.15% 117
2017
Q4
$218K Sell
3,041
-29
-0.9% -$2.2K 0.14% 120
2017
Q3
$249K Buy
3,070
+70
+2% +$5.35K 0.17% 108
2017
Q2
$212K Buy
+3,000
New +$200K 0.14% 111
2016
Q2
Sell
-3,400
Closed -$312K 123
2016
Q1
$312K Buy
3,400
+900
+36% +$81.2K 0.2% 108
2015
Q4
$253K Sell
2,500
-132
-5% -$13.7K 0.15% 114
2015
Q3
$258K Hold
2,632
0.16% 113
2015
Q2
$308K Hold
2,632
0.18% 116
2015
Q1
$258K Buy
2,632
+432
+20% +$43.9K 0.13% 128
2014
Q4
$207K Sell
2,200
-16,169
-88% -$1.67M 0.11% 130
2014
Q3
$1.96M Sell
18,369
-74
-0.4% -$7.25K 1.05% 20
2014
Q2
$1.53M Buy
18,443
+526
+3% +$40.9K 0.79% 52
2014
Q1
$1.27M Buy
+17,917
New +$1.41M 0.67% 65

Other funds holding GILD

Kingfisher Capital's GILD Position: Q3 2020 in Review

Kingfisher Capital sold out of Gilead Sciences (GILD) in Q3 2020, closing a stake of 20,744 shares — an estimated $1.6M sold.

Kingfisher Capital first reported a position in GILD in Q1 2014 and held it in 19 quarters. The position peaked at $1.96M in Q3 2014. 1,538 funds tracked by Wall St. Rank hold GILD as of Q3 2020.

  • Kingfisher Capital reported no remaining Gilead Sciences position as of Q3 2020 after selling out during the quarter.
  • Kingfisher Capital sold 20,744 Gilead Sciences shares in Q3 2020, an estimated $1.6M.
  • Kingfisher Capital first reported a position in Gilead Sciences in Q1 2014 and held it in 19 quarters.
  • Kingfisher Capital's Gilead Sciences position peaked at $1.96M in Q3 2014.
  • 1,538 funds tracked by Wall St. Rank held Gilead Sciences as of Q3 2020.

Based on Kingfisher Capital's 13F filing for Q3 2020, filed 12 Nov 2020.